H. Lundbeck A/S
HLUN-A
Rang in aandelen
#3072
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Aandeelprijs
$7.07
Marktkapitalisatie
$5.91B
Verandering (1 dag)
-4.56%
Verandering (1 jaar)
28.57%
Land
DK
Handel H. Lundbeck A/S (HLUN-A)
Categorie
Healthcare
P/B-ratio voor H. Lundbeck A/S (HLUN-A)
P/B-ratio op October 2026 TTM: 1.75
Volgens de meest recente financiële rapporten en aandelenkoers van H. Lundbeck A/S is de huidige P/B-ratio (TTM) 1.75. Eind 2024 had het bedrijf een P/B-ratio van 1.64.
P/B-ratiohistoriek voor H. Lundbeck A/S van 2004 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 1.75 | 1.69% |
| 2025 | 1.72 | 4.98% |
| 2024 | 1.64 | 11.09% |
| 2023 | 1.47 | 18.46% |
| 2022 | 1.24 | -11.90% |
| 2021 | 1.41 | 271.33% |
| 2020 | 0.38 | -1.12% |
| 2019 | 0.38 | -15.07% |
| 2018 | 0.45 | -14.02% |
| 2017 | 0.53 | -20.28% |
| 2016 | 0.66 | -9.04% |
| 2015 | 0.73 | 54.11% |
| 2014 | 0.47 | -0.25% |
| 2013 | 0.47 | -2.11% |
| 2012 | 0.48 | -3.17% |
| 2011 | 0.50 | -12.96% |
| 2010 | 0.57 | -20.84% |
| 2009 | 0.72 | -14.99% |
| 2008 | 0.85 | -8.14% |
| 2007 | 0.93 | -8.58% |
| 2006 | 1.01 | 4.11% |
| 2005 | 0.97 | 2.35% |
| 2004 | 0.95 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 3.8424 | 119.68% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| 17.3539 | 892.16% |
US
|
|
| - | - |
IT
|
